Neurotech Locks in $3.15 Million Loan for Phase III Autism Trials
Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.
- Secured $3.15 million loan against FY2026 and FY2027 R&D tax incentives
- 16% annual interest rate with maturity at end of 2027
- Funding earmarked for Phase III Autism Spectrum Disorder clinical studies
- Loan repayment tied to refundable R&D tax offsets in two tranches
- Loan supports ongoing R&D and general working capital needs
Loan Agreement Details and Financial Terms
Neurotech International Limited (ASX:NTI) has entered a secured loan agreement with Rockford RDF Pty Ltd, borrowing $3.15 million against its forecast refundable research and development (R&D) tax incentives for fiscal years 2026 and 2027. The loan carries a hefty 16% per annum interest rate, calculated daily on the outstanding balance, with a default rate climbing to 20%. An establishment fee of 1%, or $31,500, is capitalised into the loan amount.
The loan matures on 31 December 2027 but can be extended by 30 days upon payment of a fee equal to the greater of $3,000 or 1% of all outstanding amounts. Repayment is structured in two tranches, aligned with the receipt of the company's anticipated R&D tax incentive refunds for FY2026 and FY2027. The loan is secured by a first-ranking charge over these anticipated tax offsets and their proceeds.
Strategic Use of Funds for Clinical Development
The injection of non-dilutive capital is earmarked primarily to support Neurotech's Phase III clinical trials targeting Autism Spectrum Disorder (ASD), a critical stage in the development of its lead drug candidate NTI164. This funding also underpins ongoing research efforts and general working capital requirements, ensuring operational continuity during this pivotal period.
Neurotech’s Phase III program follows promising Phase II/III results demonstrating statistically significant benefits and strong safety profiles in ASD patients. The company has also secured human ethics committee clearance for these trials, marking an important regulatory milestone.
Funding Context Amid Clinical and Regulatory Progress
This loan complements recent advances in Neurotech’s clinical pipeline, including the FDA clearance for its Investigational New Drug application, which opens the door for US-based trials and bolsters its global development strategy. The company has also been awarded US patent allowances extending protection for NTI164 through 2042, reinforcing its intellectual property position.
While the loan’s interest cost is substantial, it offers a non-dilutive alternative to equity funding, preserving shareholder value during a capital-intensive phase. However, the timing and receipt of R&D tax incentives will be critical to meet repayment schedules, adding an element of financial risk tied to government processes.
Bottom Line?
Neurotech’s secured loan provides vital funding for late-stage ASD trials but hinges on timely R&D tax incentive refunds amid high-interest costs.
Questions in the middle?
- Will Neurotech’s R&D tax incentive receipts align with loan repayment timelines?
- How will the 16% interest burden impact cash flow during clinical trial progression?
- What contingencies exist if Phase III trial milestones or regulatory approvals face delays?
